Celcuity Appoints Eldon Mayer as Chief Commercial Officer
20 Fevereiro 2024 - 9:05AM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company pursuing development of targeted therapies for oncology,
today announced the appointment of Eldon Mayer as Chief Commercial
Officer. Mr. Mayer joins Celcuity with over 30 years of
biopharmaceutical commercial experience in companies ranging from
early-stage biotechs to full scale pharmaceutical companies across
many therapeutic areas, including oncology.
“Eldon is an exceptional leader with a proven track record of
building commercial organizations from the ground up to support the
launch of a biotech company’s first drug. His significant
commercial experience at multiple biopharma companies, large and
small, launching a variety of different drugs in different markets
and scaling them, make him the ideal candidate to lead the
potential commercial launch of Celcuity’s inaugural product,
gedatolisib,” said Brian Sullivan, Celcuity’s Chief Executive
Officer and co-founder. “We believe gedatolisib has a unique
opportunity to become a transformational therapy in multiple tumor
types, and Eldon has the right background to help gedatolisib
realize this potential.”
Prior to joining Celcuity, Mr. Mayer served as Executive Vice
President and Chief Commercial Officer at Eiger Biopharmaceuticals
where he led the commercial planning and execution of several
pipeline assets including international partnerships as well as the
global launch of Zokinvy® for progeria and progeroid laminopathies.
Prior to Eiger, he was Executive Vice President and Chief
Commercial Officer of Rigel Pharmaceuticals where he built and led
the commercial organization and launched Tavalisse® (fostamatinib
disodium hexahydrate) for chronic immune thrombocytopenia. Mr.
Mayer has also served as Senior Vice President of Commercial
Operations at Questcor Pharmaceuticals where he built a large
commercial team that generated over $1 billion in annual sales of
Acthar® Gel (repository corticotropin injection). Questcor was
acquired by Mallinckrodt for $5.6 billion in 2014. Earlier in his
career, he held positions of increasing responsibilities at
companies including Schering-Plough, ALZA, Chiron, and Connetics,
in functional areas including strategic planning, marketing, sales,
market research and analytics, operations and finance.
“I am excited to join Celcuity and work alongside driven,
collaborative colleagues during this pivotal time for the company,”
said Eldon Mayer. “With significant milestones for gedatolisib
approaching, I look forward to leading the commercial and marketing
efforts as we aim to bring this novel therapeutic option to the
clinic.”
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on
development of targeted therapies for treatment of multiple solid
tumor indications. The company's lead therapeutic candidate is
gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism
of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that
target PI3K or mTOR alone or together. A Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant
with or without palbociclib in patients with HR+/HER2- advanced
breast cancer is currently enrolling patients. More detailed
information about the VIKTORIA-1 study can be found at
ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201,
evaluating gedatolisib in combination with darolutamide in patients
with metastatic castration resistant prostate cancer, is expected
to be initiated in the first quarter of 2024. The company's
CELsignia companion diagnostic platform is uniquely able to analyze
live patient tumor cells to identify new groups of cancer patients
likely to benefit from already approved targeted therapies. Further
information about Celcuity can be found at Celcuity.com. Follow us
on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains statements that constitute
"forward-looking statements" including, but not limited to, our
beliefs and expectations about the commercial potential of
gedatolisib, the timeframe for clinical trials, achieving
milestones to support commercialization, and Mr. Mayer’s ability to
successfully lead Celcuity’s commercialization and marketing
activities. Forward-looking statements are subject to numerous
risks, uncertainties, and conditions, many of which are beyond our
control, such as unexpected delays in clinical trials or
unfavorable results; competition, market and regulatory issues that
may affect our ability to commercialize gedatolisib; and those
risks set forth in the Risk Factors section in Celcuity's Annual
Report on Form 10-K for the year ended December 31, 2022, filed
with the Securities and Exchange Commission on March 23, 2023.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Celcuity undertakes no obligation to update these statements for
revisions or changes after the date of this press release, except
as required by law.
Contacts:
Celcuity Inc. Brian Sullivan,
bsullivan@celcuity.com Vicky Hahne,
vhahne@celcuity.com (763) 392-0123
ICR Westwicke Maria Yonkoski,
maria.yonkoski@westwicke.com (203) 682-7167
Celcuity (NASDAQ:CELC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Celcuity (NASDAQ:CELC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024